NASDAQ
Cytek Biosciences, Inc. (CTKB) has a free cash flow growth of -176.75% as of Friday, May 29, 2026. This represents a 81.94% decrease compared to its 12-month average of -97.15%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.